• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ABBOTT IRELAND ARCHITECT AFP REAGENT KIT; KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ABBOTT IRELAND ARCHITECT AFP REAGENT KIT; KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS Back to Search Results
Model Number 3P36-25
Device Problem Low Test Results (2458)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 03/09/2021
Event Type  malfunction  
Manufacturer Narrative
(b)(4).Was this device serviced by a third party? no.An evaluation is in process.A follow-up report will be submitted when the evaluation is complete.
 
Event Description
The customer reported falsely decreased architect afp result for an (b)(6) patient that the doctor suspects hepatocellular carcinoma and is a hcv carrier due to old age.The following data was provided on 09mar2021: on (b)(6) 2020 = afp result = 28 ng/ml.On (b)(6) 2021 = afp result = 16.17 ng/ml, repeat result = 16.45 ng/ml.Other laboratory tests performed: on (b)(6) 2021 = pivka ii result = 600 mau/ml; on (b)(6) 2021 = pivka ii result = 40000 mau/ml.On (b)(6) 2021 = cea result = 4.4 ng/ml; on (b)(6) 2020 cea result = 3.5 ng/ml.On (b)(6) 2021 = ca 19-9 result = 36 ng/ml; on (b)((6) 2020 ca 19-9 result = 31.6.It was confirmed with the customer that both measurements of pivka-ii was performed by another method ((b)(4)).There was no impact to patient management reported.
 
Manufacturer Narrative
Section d: suspect medical device d4 expiration date initial: unknown; updated: 10/12/2021.Section h: device manufacturers only h4 device mfg date initial: unknown; updated: 11/05/2020.
 
Manufacturer Narrative
This follow up is submitted to populate fields d8 and/or h6 with data that had previously been provided in field h10.There is no change to the content of the data.
 
Manufacturer Narrative
Component code: g01003.The complaint investigation for potential false depressed afp results included a search for similar complaints, and review of complaint text, trending data, labeling, and device history records.Return testing was not completed as returns were not available.Historical performance of reagent lot 21153fn00 was evaluated using worldwide data.The patient data was analyzed and compared to an established control limit.This evaluation indicated that the patient median result for lot 21153fn00 is within the established control limits.Therefore, no unusual reagent lot performance was identified.Trending review determined no trends were identified for the issue for the product.Device history record review on lot 21153fn00 did not show any non-conformances or deviations.Labeling was reviewed and found to adequately address the issue under review.After review of the architect afp product use described in this ticket, it was determined that is was not in alignment with our labeling.In this case, no discrepant results were obtained.The patient was not diagnosed with nonseminomatous testicular cancer or diagnosed with cancer in general.The patient is also not pregnant.The information provided indicates that the afp assay was used outside of its intended use.Per product labeling, the distribution of architect afp values was determined in 400 specimens from apparently healthy individuals (200 males and 200 females), in 238 patients with nonmalignant diseases and in 224 patients diagnosed with malignant diseases.The observed nonparametric central 95% of the 400 apparently healthy individuals ranged from 0.89 to 8.78 ng/ml the architect afp package insert clearly indicates that the intended use of the product is as an aid in monitoring disease progression during the course of disease and treatment of patients with nonseminomatous testicular cancer and also to aid in the detection of fetal open neural tube defects (ntd).Based on the investigation architect afp reagent lot 21153fn00 is performing as intended, no systemic issue or deficiency of the architect afp reagent was identified.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARCHITECT AFP REAGENT KIT
Type of Device
KIT, TEST, ALPHA-FETOPROTEIN FOR NEURAL TUBE DEFECTS
Manufacturer (Section D)
ABBOTT IRELAND
finisklin business park
sligo F91VY 44
EI  F91VY44
MDR Report Key11590396
MDR Text Key246816641
Report Number3008344661-2021-00072
Device Sequence Number1
Product Code LOK
UDI-Device Identifier00380740081317
UDI-Public00380740081317
Combination Product (y/n)N
PMA/PMN Number
P120008
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type foreign,health professional
Type of Report Initial,Followup,Followup,Followup
Report Date 06/15/2021
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/30/2021
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date10/12/2021
Device Model Number3P36-25
Device Catalogue Number03P36-25
Device Lot Number21153FN00
Was Device Available for Evaluation? No
Date Manufacturer Received06/14/2021
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Treatment
ARC I2K PROC MOD, 03M74-01, ISR54324; ARC I2K PROC MOD, 03M74-01, ISR54324; ARC I2K PROC MOD, 03M74-01, ISR54324; ARC I2K PROC MOD, 03M74-01, ISR54324
Patient Age80 YR
-
-